A Phase II Study of Abiraterone with or without Cabazitaxel in Patients with Metastatic Castration-Resistance Prostate Cancer

Protocol
14-046
Full Title
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Phase
II
Purpose

Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies; these are called “castration-resistant prostate cancers” (CRPC).

Abiraterone acetate and cabazitaxel are drugs that are both approved for treating CRPC. Abiraterone, which is given with prednisone, works by blocking the production of cancer-fueling testosterone by inhibiting an enzyme called CYP17. Cabazitaxel makes the “skeleton” in some cancer cells very stiff, so the cells can no longer grow or divide. Both abiraterone and cabazitaxel are given to men whose cancer has progressed despite docetaxel chemotherapy.

In this study, researchers are assessing the safety and effectiveness of combining abiraterone, prednisone, and cabazitaxel in men with CRPC who have not yet received docetaxel. This approach is considered investigational. Patients will be randomly assigned to one of two groups:

  • One group will receive abiraterone and prednisone, but will not receive cabazitaxel unless the cancer continues to grow despite abiraterone/prednisone therapy.
  • The second group will receive all three drugs together.

Abiraterone and prednisone are taken orally (by mouth), while cabazitaxel is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have castration-resistant prostate cancer that has not previously been treated with chemotherapy.
  • Patients must recover from the serious side effects of prior treatments before entering the study.
  • Patients must be able to be walk and do routine activities for more than half of their normal waking hours.
  • This study is for men age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Susan F. Slovin at 646-422-4470.

Disease(s)
Prostate Cancer: Metastatic Disease after Hormone-Reducing Therapy
Locations
Related Diseases